Abstract O 6 -methylguanine DNA methyltransferase (MGMT) promoter methylation is a predictive biomarker for benefit from alkylating chemotherapy, specifically temozolomide (TMZ), in glioblastoma, the most common malignant intrinsic brain tumor. Glioma-initiating cells (GIC) with stem-like properties have been associated with resistance to therapy and progression.
Glioblastomas, the most malignant primary brain tumors in adults, are characterized by their infiltrative growth pattern and resistance to radiotherapy and cytotoxic chemotherapy. Current multimodality treatment approaches include surgery, radiotherapy, and alkylating agent chemotherapy using temozolomide (TMZ) ); yet, recurrence is inevitable and median survival is still in the range of 12-17 months (Johnson and O'Neill 2012; Gramatzki et al. 2016) . Tumors lacking methylation of the promoter region of the O 6 -methylguanine DNA methyltransferase (MGMT) gene, which encodes a DNA repair protein, are especially prone to early progression during standard chemoradiotherapy (Hegi et al. 2005) .
Glioma-initiating cells (GIC), also referred to as stem-like glioma cells, are a subpopulation of cells within a glioma considered to maintain a pool of highly treatment-resistant cells responsible for treatment failure and progression (Lathia et al. 2015) . The role of MGMT specifically in the GIC compartment has been addressed in various experimental approaches, but no uniform concept has emerged (Beier et al. 2008; Blough et al. 2010; Sciuscio et al. 2011) . In a panel of 10 paired samples of glioblastomas and their derived sphere cultures, MGMT promoter methylation was highly enriched in sphere cells, with MGMT protein levels being accordingly reduced (Sciuscio et al. 2011) . Glioma-derived stem cells with sphere-forming capacity have even been suggested as preferential targets of TMZ-induced tumor cell depletion (Beier et al. 2008) . Other groups have shown a heterogeneous pattern of resistance to TMZ in GIC cultures, with resistant as well as sensitive GIC displaying heterogeneous MGMT promoter methylation, concluding that its mere presence does not predict sensitivity to TMZ. Yet, MGMT protein levels correlated with TMZ sensitivity in this panel of 20 GIC (Blough et al. 2010) . In cultures of side populationderived neurospheres, stem cell properties, and MGMT expression were enriched compared to the bulk population of tumor cells (Bleau et al. 2009 ). Yet, more recently the side population has been proposed to consist essentially of nonneoplastic cells (Golebiewska et al. 2013 ) which would explain increased MGMT expression. Here, we explore the relationship between the stemness phenotype of cultured glioma cells and MGMT expression in vitro and link nuclear factor kappa B (NF-kB) activation with consecutive MGMT induction to stemness and chemoresistance.
Materials and methods
Reagents TMZ was provided by Schering-Plough (Kenilworth, NJ, USA). A stock solution of TMZ at 200 mM was prepared in dimethylsulfoxide (DMSO) and stored at À20°C. Human MGMT antibody was purchased from Alpha Diagnostics (San Antonio, TX, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (EB07069) (RRID:AB_2247304) was obtained from Everest Biotech (Oxfordshire, UK). b-Actin antibody (sc-1616) (RRID: AB_630836) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). BAY 11-7082 (Selleckchem, Houston, TX, USA) was prepared as 50 mM stock solution in DMSO. Cilengitide (EMD121974) was kindly provided by Merck KGaA (Darmstadt, Germany). GLPG0187 was kindly provided by Galapagos NV (Mechelen, Belgium). Cyclo-(Arg-Ala-Asp-DPhe-Val) peptide cyclo-Arg-Ala-Asp-DPhe-Val was purchased from Bachem AG (Bubendorf, Switzerland). Bone morphogenetic protein-4 was from R&D (Minneapolis, MN, USA). O 6 -benzylguanine (O 6 -BG) and all other reagents, unless indicated otherwise, were purchased from Sigma (St. Louis, MO, USA).
Cell lines
The human glioma-initiating (stem-like) cell lines (GIC) GS-2, GS-5, GS-7, GS-8, GS-9 (Gunther et al. 2008) , T-325 (Lemke et al. 2014) , ZH-161, and ZH-305 (Silginer et al. 2016; Stojcheva et al. 2016) were maintained as sphere (S) cultures in Neurobasal Medium â supplemented with 2% B-27 supplement, 1% GlutaMAX (Invitrogen, Life Technologies, Carlsbad, CA, USA), 20 ng/mL epidermal growth factor, 20 ng/mL fibroblast growth factor, and 32 IE/mL heparin. The human glioma cell line T98G (RRID: CVCL_0556) was purchased from the American Type Culture Collection (Rockville, MD, USA). The glioma cell lines LN-18 (RRID:CVCL_0392), LN-229 (RRID:CVCL_0393), and LN-308 (RRID:CVCL_0394) were kindly provided by N. de Tribolet (Lausanne, Switzerland). LN-18_R cells have been described (Happold et al. 2012) . These long-term cell lines (LTC) were commonly cultured as monolayers (M) in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum (FCS) and 2 mM glutamine from Gibco Life Technologies (Carlsbad, CA, USA). LN-229_MGMT and LN-229_Neo cells have been described (Hermisson et al. 2006) . In selected experiments the culture conditions were switched for both GIC and LTC, as outlined below. Cells isolated from freshly resected human glioblastoma tumor tissue were collected after written informed consent of the patients and approval by the institutional review board. Briefly, these cells were extracted from tumor tissue by dissociating tissue with 10 mg/ml collagenase/ dispase (Roche, Basel, Switzerland) and gentle rotation in MACS Ctubes (Miltenyi biotech, Cologne, Germany). Cells were counted and 20 lL of FcR blocking reagent and 20 lL of CD133 microbeads (Miltenyi biotech) were added per 10 7 cells. Cells were incubated for 45 min at 4°C, passed through a 40 lm cell strainer, and then passed through an LS column placed in the magnetic field of the MACS separator. The passing CD133-negative population was passed a second time through a second column to get a purer CD133-negative population. CD133-positive cells remained in the column and were collected separately by forceful washing.
Quantitative PCR
Total RNA was prepared using the NucleoSpin System (MachereyNagel AG, Oensingen SO, Switzerland) and transcribed into cDNA. For real-time (quantitative) quantitative polymerase chain reaction (qPCR), cDNA amplification was monitored using SYBRGreen chemistry on the 7300 real-time PCR System (Applied Biosystems, Zug, Switzerland). The conditions were: 40 cycles, 95°C/15 sec, 60°C/1 min. Data analysis was done using the DDC T method for relative quantification. The following specific primers were used: GAPDH fwd: 5 0 -CTCTCTGCTCCTCCTGTTCGAC-3 0 , GAPDH rv: 
Single-cell gene expression analysis correlation experiments Single-cell gene expression analysis has been described (Stahlberg et al. 2013 ). Low quality cells that did not express the housekeeping genes ARF-1 or ARF-1 were discarded; 481 cells from six patients were included in the analyses. Cq values were converted to expression levels using the equation Log 2 Ex = C q LOD (Limit of Detection) -Cq with a LOD C q of 25 and data were transformed using asinh transformation. Pearson`s correlation coefficients were computed using the corrplot R package version 0.77 and Bonferroni correction was applied to adjust for multiple hypothesis testing. Scatterplots of significant correlations were plotted using the ggpubr R package version 0.1.2.
Spherogenicity and clonogenicity assays S cells were seeded at 500 cells per well of 96-well plates in neurobasal (NB) medium, treated 24 h later as indicated, and consecutively maintained in NB medium. For adherent M cultures, clonogenic assays were performed by seeding 100 cells (LN-229) or 300 cells (all other LTC or M cells) per well in 96-well plates and allowed to adhere overnight. The cells were exposed to TMZ at the indicated concentrations for 24 h in serum-free medium, followed by an observation period for 7-14 days in the same medium. In the experiments involving O 6 -BG, the cells were pretreated with O 6 -BG or DMSO control for 2 h prior to TMZ application. Cell density was assessed by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT) assay for S conditions and by crystal violet staining for M conditions. Representative studies confirmed that the data obtained like that correspond well to data based on actual counts of spheres or colonies.
Immunoblot analysis
Cells treated as indicated were lysed on ice in radioimmunoprecipitation assay (RIPA) lysis buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 lg/mL leupeptin, 1 mM ethylene glycol-bis(baminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) supplemented with 19 complete inhibitor mix (Roche Diagnostics, GrenzachWyhlen, Germany). Precleared cell lysates, mixed and boiled with Laemmli buffer containing b-mercaptoethanol, were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (GE Healthcare; Little Chalfont, Buckinghamshire, UK). After blocking in Trisbuffered saline containing 5% skim milk and 0.05% Tween 20, the blots were incubated overnight at 4°C with primary antibodies and 1 h at 21°C for secondary antibodies. Visualization of protein bands was done using horseradish peroxidase-coupled secondary antibodies (Santa Cruz Biotechnology) and enhanced chemiluminescence (Pierce/Thermo Fisher, Madison, WI, USA).
Reporter assay Cells were either transfected by electroporation directly (for S cells) or by Lipofectamine 2000 reagent 24 h after seeding to a 96-well plate with 20 000 cells/well (for M cells), with 200 ng of pNF-jBLuc plasmid containing a firefly luciferase gene designed to detect NF-jB signaling activity, together with 20 ng of the control renilla plasmid pRL-CMV (Hermisson and Weller 2003) . GIC were seeded at a density of 50 000 cells/well in 96-well plates after transfection. Further treatment was performed 18 h later, and cells were lysed 6 h posttreatment and luciferase activity was measured.
Transient transfection GIC were dissociated using Accutase cell detachment solution (PAA Laboratories, Pasching, Austria), and 2 9 10 6 cells were transfected using the Neon Transfection System electroporation device and kit (Invitrogen, Life Technologies) with 100 nM specific or control. Hereafter, cells were allowed to recover for a day under neurobasal conditions, and seeded for either survival assays or protein lysate isolation as described above.
Proliferation assays
Cells were seeded at a density of 1 9 10 5 cells/well in a 96-well plate with six well replicates per time point, and left to grow for the indicated time points. Analysis was done by MTT assay as described above, and normalized to baseline time point.
Flow cytometry
For cell cycle analysis, GIC and LTC were harvested, fixed, and washed with phosphate-buffered saline. Hereafter, RNA was digested with RNase A (Carl Roth AG, Karlsruhe, Germany), DNA stained with propidium iodide (PI) (50 lg/mL) and fluorescence was recorded with BD FACSVerse flow cytometer (BD, Heidelberg, Germany). For AnnexinV/PI flow cytometry, cells were incubated with FITC-labeled AnxV-fluorescin isothiocyanate and PI for 20 min. Fluorescence was recorded with a BD FACSVerse flow cytometer. PI-positive (necrotic) or AnxV-positive (apoptotic) cells or double positive were counted as dead.
Statistical analyses
Data are representative of experiments independently performed three times with similar results unless indicated otherwise with the exception of the freshly resected tumor tissue cell-based experiments. Viability and proliferation studies were performed using triplicate wells. Where indicated, analysis of significance was performed using the two-tailed Student's t-test. Correlation analysis was done by Spearman test. No randomization or blinding was performed in this study. Study was not pre-registered.
Results
Sphere cultures of GIC are more resistant to TMZ than adherent cultures GIC are considered to promote treatment resistance in glioblastoma and to retain an expression signature related to stemness that is gradually lost when multi-lineage differentiation and adherent monolayer growth are induced by exposure to FCS-containing medium ( Fig. 1a and b ; Fig S1a) (Gunther et al. 2008; Happold et al. 2014) . However, we noted that merely shifting of GIC cells from S to M conditions was associated with greatly enhanced sensitivity to TMZ ( Fig. 1c  and d) . The EC 50 values were shifted up to 10-fold in all GIC except for T-325 and GS-9. In ZH-305, the effect was even reversed (Fig. 1e) . Limiting dilution assays were performed to further characterize TMZ sensitivity of S cells to TMZ as function of cell density (Fig. S1b) . No major changes in cell cycle distribution or proliferation rate were seen between S and M cells (Fig. 1f and g ). Moreover, AnxV/PI flow cytometry did not confirm relevant cell death after exposure to TMZ at clinically relevant concentrations (Fig. S1c) .
High MGMT expression confers TMZ resistance in S cultures
We next investigated whether the loss of resistance to TMZ induced by switching from S to M culture conditions was associated with changes in MGMT expression. While most M cultures exhibited only minor decreases in MGMT mRNA expression levels compared with S cultures (Fig. 2a) , we found consistent reduction of MGMT protein levels in M cultures (Fig. 2b) . GS-9 and ZH-305, which did not show decreased EC 50 values when switched to M conditions, did not express MGMT either under S or M conditions. There was strong correlation between MGMT mRNA levels determined by qPCR and TMZ sensitivity defined by EC 50 values in clonogenicity assays (r = 0.79, p = 0.0003) (Fig. 2c) . To confirm that the changes in MGMT levels are responsible for the sensitization to TMZ during the S?M transition, we preexposed the cells to the MGMT pseudosubstrate inhibitor, O 6 -BG, for 2 h before TMZ exposure. Consumption of MGMT levels by O 6 -BG within 72 h was verified by immunoblot analysis. Indeed, pre-exposure to O 6 -BG shifted the sensitivity of S cultures to TMZ to the range of M cultures (for GS-2) or lower (for GS-5) in clonogenic survival assays (Fig. 2d) .
MGMT expression correlates with expression of stemness markers Single-cell gene expression analysis performed from freshly resected glioma tissue confirmed positive correlation of MGMT with various stem cell markers, although not Musashi (Fig. 3a) . Additionally, to confirm differential MGMT expression ex vivo, we investigated MGMT expression in isolated CD133-positive cells, considered stem-like, versus CD133-negative sorted cells, from freshly resected tumor tissues of five glioblastoma patients. MGMT mRNA levels were increased at least twofold in CD133+ cells in all patients (Fig. 3b) . Conversely, induction of differentiation by bone morphogenetic protein-4 decreased MGMT protein levels in three out of four S cell lines (Fig. 3c) , as well as CD133 mRNA expression in three out of four cell lines except for a reversed effect in T-325, while increasing GFAP mRNA expression (Fig. 3d) .
Impact of culture conditions on MGMT expression in glioma cells
To better understand the regulation of MGMT expression in S versus M cells, we studied the time course of MGMT loss upon S?M transition in more detail. The switch of GS-2 and GS-5 S to M conditions led to a rapid drop of MGMT levels in GS-5 (d1) and a delayed decline in GS-2 (d12) (Fig. 4a) . Conversely, when the M cells were returned to S conditions, they formed spheres again and accumulated MGMT protein, with GS-2 displaying earlier protein level changes (d1) than GS-5 (d5), indicating that this effect, albeit consistent, had variable time kinetics in different model systems (Fig. 4b) . MGMT regulation was directly or indirectly linked to the additional components of the NB medium since cells maintained in NB medium only did not accumulate MGMT to the extent of cells maintained in NB medium plus supplements (Fig. 4c) . Cell death because of lack of supplements was excluded as a cause for lower MGMT levels (Fig. 4d) . In order to assess whether a specific medium supplement was responsible for the regulation of MGMT expression in S cells, we starved GS-2 and GS-5 from individual medium supplements. We found that, while sphere formation and volume were reduced when growth factors were removed from the medium (data not shown), the levels of MGMT did not significantly vary in S cells deprived from either fibroblast growth factor, epidermal growth factor, B27, or heparin for 3 days (Fig. 4e) , a time point where the switch to DMEM had already strongly decreased MGMT levels (Fig. 4a) . Moreover, FCS deprivation did not induce MGMT in GS-5 maintained in monolayer conditions; neither did the addition of FCS alone to NB medium significantly decrease MGMT levels (Fig. 4e) . Although the media supplements, either in NB medium as growth factors or in DMEM as FCS appeared to have no direct impact on MGMT expression per se, cell morphology was quite dependent on the medium in which the cells were grown (Fig. 4f) , and cells neither attached in DMEM without FCS nor formed spheres in NB without supplements. To finally exclude that attachment or detachment regulate MGMT expression levels, we cultured GIC sphere cells in complete NB medium for up to 6 days either with or without supplementation of 10% FCS to induce attachment. However, only a minor reduction in MGMT protein levels was observed upon attachment ( Fig. 4g and h ). To exclude a sole effect of induction of attachment by FCS in this context, expression of MGMT under modulation of attachment by the integrin inhibitors cilengitide or GLPG0187 was analyzed. No significant regulation of MGMT, neither on mRNA nor protein level, was observed in S or M cells exposed to either integrin inhibitor (Fig. S2a and b) . Single-cell gene expression analysis did not confirm negative correlations for expression of MGMT versus that of several adhesion molecules (Fig. S2c) . Additionally, to exclude that GIC cells under S conditions express higher levels of MGMT because of higher hypoxia levels within the spheres, driving the cells into a more stem cell state, we analyzed MGMT expression levels in MGMT-expressing LTC or GIC. Intriguingly, cells kept under hypoxic conditions displayed reduced levels of MGMT on both mRNA and protein levels. Induction of hypoxia was verified by expression analysis of the hypoxia marker, carbonic anhydrase 9, which also confirmed higher baseline levels of hypoxia in S cultures (Fig. S2d-f) . Finally, sphereformation capacity was not impacted by silencing of MGMT or by O 6 -BG-mediated MGMT consumption (Fig. S3a-c) .
NF-jB, a transcriptional regulator of MGMT, is overexpressed in GIC NF-jB is a transcription factor previously described to be a positive regulator of MGMT (Lavon et al. 2007 ). Therefore, we investigated whether NF-jB impacts MGMT regulation in human GIC cells as well. Expression of NF-jB did not differ consistently in GS-2 and GS-5 S versus M cells on mRNA levels; however, NF-jB subunit p65 protein levels were increased in S cells of GS-2 and GS-5 (Fig. 5a) . Moreover, we confirmed a higher activity of NF-jB in S cells by luciferase reporter assay in GS-2 and GS-5 S versus M cells, an activity that was suppressed by pre-exposure to the NF-jB inhibitor, BAY 11-7082 (Fig. 5b) . Likewise, pre-exposure to BAY 11-7082 significantly reduced MGMT protein levels in a concentration-dependent manner for at least 72 h in GS-2, (Fig. 5c) ; in the latter cell lines, higher concentrations of the inhibitor did, however, result in cell death (data not shown), as reflected by protein degradation shown as a gradual loss of actin (Fig. 5c) . Likewise, GIC exposure to moderate concentrations of BAY 11-7082 over a longer period in the context of spherogenicity assays resulted in evolution of cell death after 7 days, demonstrating the prosurvival function of NF-jB, but precluding formal analyses of BAY 11-7082-mediated sensitization to TMZ in spherogenicity assays (data not shown). We confirmed the NF-jB-mediated regulation of MGMT by an siRNAmediated approach using p50/p65si to silence NF-jB expression (Fig. 5d) . A second siRNA pool was used to validate the results in GS-2, GS-5, T-325, and ZH-161 cells (Fig. 5e ).
MGMT expression pattern in LTC
To better understand this hitherto undescribed regulation of MGMT expression, we next asked whether the differential expression of MGMT in S versus M cultures was specific to the GIC phenotype. LN-18 and T98G cells, the only MGMTexpressing LTC in our panel (Hermisson et al. 2006) , formed spheres when grown in NB medium, and displayed a strong increase in MGMT levels when shifted to S conditions ( Fig. S4a and b) . Similar experiments were performed as a control for two further LTC, LN-229 and LN-308, which do not express MGMT as a result of MGMT promoter methylation (Fig. S4c) . S cultures of these cells did not acquire MGMT expression (Fig. S4d) . Again, silencing of MGMT in MGMT-expressing LN-18 cells, or overexpression of MGMT in methylated LN-229 cells, did not impact their sphere-formation capacity ( Fig. S4e and f) . LN-229 cells engineered to over-express MGMT showed a higher level of TMZ resistance than control cells under either conditions, although the M-to-S shift per se conferred increased TMZ resistance in the absence of MGMT induction (Fig. S4g) .
Discussion
The role of MGMT promoter methylation as a predictor of benefit from alkylating chemotherapy in glioblastoma is well established (Weller et al. 2010) . Furthermore, the impact of GIC for maintenance of the malignant phenotype of gliomas has been studied extensively over the last years (Lathia et al. 2015) . Yet, the regulation of MGMT expression in GIC has remained poorly understood.
Here, we report that GIC cultures transferred from S to M culture conditions exhibit reduced MGMT expression ( Fig. 2a and b ) associated with enhanced sensitivity to TMZ (Fig. 2c-e) . Increased TMZ resistance in S cells was not merely linked to reduced exposure of sphere cells to TMZ, compared with M cells which grow as a flat monolayer, since there was no increase in the resistance to TMZ from M-to-S cells in the two cell lines lacking MGMT expression, GS-9 and ZH-305. The changes in MGMT expression in cells lacking MGMT promoter methylation could be linked neither to direct stimulating effect of a specific component of the sphere culture medium nor to a suppressive effect of FCS (Fig. 4) . A relevant association of MGMT expression with cell attachment or higher MGMT expression caused by hypoxia within the spheres was excluded, too (Fig. S2) . Interestingly, the same pattern of increased MGMT protein expression was seen in two LTClacking MGMT promoter methylation when grown in sphere conditions ( Fig. S4a and b) . However, MGMT expression and sphere formation appear not to be directly linked, as depletion of MGMT by either gene silencing or consumption by the pharmacological inhibitor O 6 -BG did not result in impaired sphere formation of the cells, neither in GIC nor LTC (Figs S3 and 4E) . In glioblastoma cells isolated from freshly resected tumor tissue and sorted for the stem cell marker CD133, increased MGMT expression was found in the CD133-positive population (Fig. 3b) (Liu et al. 2006) . Admittedly, CD133 remains a controversial stem cell marker (Beier et al. 2007) ; however, lacking a more reliable validated marker, sorting for CD133 remained a practicable approach for fresh tumor tissue. Moreover, a positive correlation between MGMT and common stemness markers was confirmed by single-cell gene PCR, too (Fig. 3a) .
NF-jB, a transcription factor regulating cell survival and proliferation in several tumor entities (Naugler and Karin 2008) , is also constitutively active in malignant brain tumors. It has been linked to epidermal growth factor receptor activity in glioblastoma via the PI3-kinase/Akt signaling axis (Kapoor et al. 2004) , as well as to resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptotic cell death (Bredel et al. 2006) . Pharmacological inhibition of NF-kB was shown to induce cell death preferentially in glioblastoma cells and not in normal astrocytes (Zanotto-Filho et al. 2011) . Overall, NF-kB has emerged as a focus of research for therapeutic approaches to block its downstream signaling pathway, and thus represents a potential target in tumor therapy. Several direct or indirect NF-kB inhibitors are available, such as sulfasalazine (Hermisson and Weller 2003) , some of which have been used in clinical trials in chronic inflammatory disorders with clinical benefit and tolerable side effects (Combe et al. 2009 ). Positive effects were additionally seen for long-term outcome in patients with rheumatoid diseases, with sustained benefits of persistent disease suppression in follow-up studies after Luciferase reporter assays were performed in GS-2 and GS-5 S or M cells exposed to either BAY 11-7082 (15 lM) or control. Normalized luciferase expression indicates NF-kB activity. Plates were stopped 24 h after plasmid transfection and 6 h after inhibitor exposure. (c) GS-2, GS-5, T-325, or ZH-161 S cells exposed to the NFkB inhibitor BAY 11-7082 at increasing concentrations as indicated or dimethylsulfoxide (DMSO) control were assessed for MGMT protein levels by immunoblot at different time points. Actin served as control. (d) GS-2 or GS-5 cells were transfected either with NF-kB subunits p50/p65 siRNA or scrambled control and MGMT protein levels were assessed at different time points; gene silencing of p50/p65 was confirmed on protein levels. Actin served as control. (e) The same cells as in C were transfected either with another siRNA pool for NF-kB subunits p50/p65 or scrambled control and MGMT protein levels were assessed. Actin served as control.
several years (van Rossum et al. 2007) . A phase 1/2 prospective study using sulfasalazine in progressive WHO III or IV glioma was terminated early after the interim analysis; however, as the investigated cohort comprised 10 patients until termination, all with recurrent, large tumors and low Karnofsky performance score (median KPS: 50), those results must be interpreted with caution (Robe et al. 2009 ). Finally, NF-kB has been described as a regulator of MGMT expression in glioma cells (Lavon et al. 2007 ). In our model, we confirmed a decrease in MGMT protein levels after inhibition of NF-kB, either by pharmacological inhibition or by a siRNA-mediated approach, therefore linking NF-kB to MGMT expression in GIC cells cultured under S conditions (Fig. 5) . The NF-jB inhibitor BAY 11-7082, however, induced global cell death of inhibitor-exposed cells over several days (Fig. 5c ) and prohibited comparative viability assays, probably because of the utmost importance of this transcription factor for cell survival, preventing any cell growth after its complete blockage. Still, NF-kB emerges as a responsible regulator of MGMT expression in GIC S cells in our model, making this transcription factor an even more relevant putative target to therapeutic approaches, considering the indisputable relevance of stem-like cells for glioblastoma malignancy and their high resistance to therapy.
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